Bedfont Scientific

Founded in 1976, Bedfont Scientific designs and manufactures innovative breath analysis solutions that support the diagnosis and monitoring of respiratory and metabolic conditions. Its flagship focus is FeNO (Fractional Exhaled Nitric Oxide) testing, a gold-standard biomarker for asthma diagnosis and management, complemented by a portfolio of devices for gastrointestinal disorders and smoking cessation.

Bedfont’s best-in-class product portfolio is distributed in more than 70 countries through a network of over 100 partners, making its solutions accessible across both primary and secondary healthcare settings worldwide. Trusted by clinicians for their accuracy, ease of use, and accessibility, Bedfont devices support better patient outcomes and have become a reference in breath analysis.

The company is headquartered in Maidstone, United Kingdom, with in-house R&D, regulatory, and manufacturing expertise, and employs over 60 highly skilled professionals dedicated to advancing global standards of care.